EUCTR2007-001439-74-IT进行中（未招募）不适用
A phase II, randomized trial of chemioradiation with or without Panitumumab in subjects with unresected, locally advanced squamous cell carcinoma of the head and neck - AMG 954 Panitumumab
AMGEN S.P.A.0 个研究点目标入组 150 人开始时间: 2007年12月10日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically or cytologically confirmed SCC of oral cavity, oropharynx, hypopharynx, or larynx Stage III or Stage IVa-b disease (M0) according to the American Joint Committee on Cancer (AJCC) staging manual 6th edition ECOG performance status of 0 or 1 Bidimensionally measurable disease ≥ 10mm in at least 1 dimension Man or woman ≥ 18 years of age Hematological function, as follows ( ≤ 10 days prior to randomization): o Absolute neutrophil count (ANC) ≥ 1.5 x 109/L o Platelet count ≥ 100 x 109/L o Hemoglobin ≥ 9 g/dL Renal function, as follows ( ≤10 days prior to randomization): o Creatinine clearance ≥ 50 mL/min as calculated from a 24 hour urine collection (required for subjects with serum creatinine > ULN) or calculated by the Cockcroft-Gault method (refer to Section 4.1.3): Hepatic function, as follows (≤10 days prior to randomization): o Aspartate aminotransferase (AST) ≤ 2 x ULN o Alanine aminotransferase (ALT) ≤ 2 x ULN o Total bilirubin ≤ 2 X ULN Metabolic function, as follows (≤ 10 days prior to randomization): o Serum magnesium ≥ LLN Each subject must give written informed consent before participating in the any study specific procedure, enrollment or receiving any study medication Negative pregnancy test ≤ 72 hours prior to randomization (females of child bearing potential)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Primary tumor of the nasopharynx, sinuses, salivary gland, or skin Prior (or concomitant) malignancy (except non-melanomatous skin cancer or in situ cervical cancer), other than the study disease (SCCHN), unless treated with curative intent with no evidence of disease for ≥ 3 years Prior anti-EGFr antibody therapy (eg, cetuximab) or treatment with small molecule tyrosine kinase inhibitors of EGFr (eg, gefitinib, erlotinib, lapatinib) Prior surgery for SCCHN (except nodal sampling or biopsy for study disease) Prior radiotherapy in the planned field Prior systemic chemotherapy for the study cancer Major surgery ≤ 28 days before randomization or minor surgery ≤ 14 days before randomization with the exception that feeding tube placement, dental extractions, central venous catheter placement, and biopsies (endoscopic or otherwise), and nodal sampling are allowed at any time prior to randomization Subjects requiring prophylactic tracheostomy Known allergy or hypersensitivity to any component of the study drugs Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year prior to randomization Chronic obstructive pulmonary disease resulting in hospitalization due to pneumonia or respiratory decompensation ≤ 6 months prior to screening History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on screening chest CT scan Active infection requiring systemic treatment or any uncontrolled infection ≤ 14 days prior to randomization. Any uncontrolled condition, which, in the opinion of the investigator, would interfere in the safe and timely delivery of study treatment Known positive test for human immunodeficiency virus (HIV) infection, hepatitis C virus, chronic active hepatitis B infection or any co-morbid disease that would increase risk of toxicity Pregnant or breast-feeding women Men not willing to use adequate contraception precautions for the duration of the study and for 1 month following the last administration of study treatment Women of childbearing potential not using adequate contraception precautions for the duration of the study and for 6 months following the last administration of study treatment Subject unwilling or unable to comply with study requirements Participation in other investigational device or drug studies ≤ 30 days before randomization Previously randomized into this study Any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures
研究者
相似试验
进行中（未招募）
不适用
A Phase 2, Randomized Trial of Chemoradiation with or withoutPanitumumab in Subjects with Unresected, Locally Advanced Squamous CellCarcinoma of the Head and NeckEUCTR2007-001439-74-FIAmgen Inc150
进行中（未招募）
不适用
A Phase 2, Randomized Trial of Chemoradiation with or withoutPanitumumab in Subjects with Unresected, Locally Advanced Squamous CellCarcinoma of the Head and NeckEUCTR2007-001439-74-HUAmgen Inc246
进行中（未招募）
1 期
A Phase 2, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and NeckAdvance Squamous Cell Carcinoma of the Head and NeckMedDRA version: 9.1 Level: LLT Classification code 10060121 Term: Squamous cell carcinoma of head and neckEUCTR2007-001439-74-GBAmgen Inc246
进行中（未招募）
不适用
A Phase 2, Randomized Trial of Chemoradiation with or withoutPanitumumab in Subjects with Unresected, Locally Advanced Squamous CellCarcinoma of the Head and NeckAdvance Squamous Cell Carcinoma of the Head and NeckMedDRA version: 9.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2007-001439-74-DEAmgen Inc246
已完成
2 期
A Randomized phaseII trial of chemoradiotherapy with UFT versus S-1 for low rectal cancerrectal cancer,lower tumor margin is below the peritoneal reflectionJPRN-UMIN000001704Tokushima university60